Navigating key news stories in pharma

Subscribe

Featured Stories

Featured
INTERPHEX 2026: The Multimodal Future of Sterile Manufacturing
Strategy
INTERPHEX 2026: The Multimodal Future of Sterile Manufacturing
Strategy

Automation and living contamination control strategies are helping to answer some of industry’s most pressing sterile manufacturing challenges, explains Dr. Laura Moody from Syntegon.

Read More →
Strategy
News
INTERPHEX 2026: The Multimodal Future of Sterile Manufacturing
Strategy
INTERPHEX 2026: The Multimodal Future of Sterile Manufacturing
Strategy

Automation and living contamination control strategies are helping to answer some of industry’s most pressing sterile manufacturing challenges, explains Dr. Laura Moody from Syntegon.

Read More →
Strategy
INTERPHEX 2026: Embedding Intelligence into Bioprocessing
Strategy
INTERPHEX 2026: Embedding Intelligence into Bioprocessing
Strategy

Customized engineering and embedded sensors are helping to turn passive single-use assemblies into intelligent, data-rich assets, reveals Rich Jones from Phillips Medisize.

Read More →
Strategy
INTERPHEX 2026: Managing Data Integrity in a Multimodal Pipeline
Strategy
INTERPHEX 2026: Managing Data Integrity in a Multimodal Pipeline
Strategy

Automated and single-use technologies are offering companies the transparency and agility needed for the newer, more complex drugs in the pipeline, explains Mike D’Avanzo from Alcami.

Read More →
Strategy

R&D

Featured
AbbVie Targets Obesity Market with Novel Drug
AbbVie Targets Obesity Market with Novel Drug

Phase I trial results for the company’s novel long-acting amylin analog, have demonstrated significant potential for patients to lose up to 9.79% of body weight in 12–13 weeks with no serious adverse events.

NOFLU Consortium Awarded Contract Worth Up to EUR 148 Million
NOFLU Consortium Awarded Contract Worth Up to EUR 148 Million

The funding, which is part of a larger investment commitment from the European Commission, will be used to progress Ethris’ differentiated mRNA vaccine technology as a treatment for pandemic flu.

Preclinical Study Finds Nanotrastuzumab to be Comparable with Herceptin HYLECTA
Preclinical Study Finds Nanotrastuzumab to be Comparable with Herceptin HYLECTA

The nanoparticle suspension formulation was found to mirror the reference product closely in terms of AUC, Cmax, and Tmax across a 21-day Göttingen minipig study performed by Charles River Laboratories.

Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment
Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment

The company’s fixed-dose combination treatment demonstrated superior efficacy to its individual components and was shown to be safe and well-tolerated, consisted with other incretin and amylin-based therapies.

Expansion

Featured
Lonza Launches Media Development Lab to Optimize Media Formulations
Lonza Launches Media Development Lab to Optimize Media Formulations

The new service, which is available at Lonza’s Singapore site, aims to help bioprocessing customers improve scalability, reduce manufacturing risk, and accelerate development timelines.

ESTEVE CDMO Expands Spray Drying Capacity in Girona
ESTEVE CDMO Expands Spray Drying Capacity in Girona

Plans for a further 3,000-square-metre spray drying and high-potency containment unit at Celrà facility in Girona, Spain, have been announced by the CDMO.

Wilmington PharmaTech Expands U.S. API Manufacturing Capacity
Wilmington PharmaTech Expands U.S. API Manufacturing Capacity

The company will add new reactor suites to its Delaware campus, increasing its API reactor capacity by more than double and enabling the company to meet new demand for high-quality domestic manufacturing.

LYOCONTRACT and Syntegon Break Ground on Freeze-Drying Facility in Germany
LYOCONTRACT and Syntegon Break Ground on Freeze-Drying Facility in Germany

The German contract manufacturer is expanding its lyophilization capacity with a complete production line from equipment supplier Syntegon, as demand for sterile freeze-dried pharmaceuticals continues to grow across the sector.

Dealmaking

Featured
Partnership Forms for the Development of Inhaled Antiviral Treatments
Partnership Forms for the Development of Inhaled Antiviral Treatments

Aptar Pharma has entered into a technical collaboration with COVIRIX Medical to evaluate its handheld dry powder inhaler device with broad‑spectrum antiviral compounds for high‑risk respiratory viruses.

Alliance Forms to Automate Cell and Gene Therapy Manufacturing
Alliance Forms to Automate Cell and Gene Therapy Manufacturing

San Diego-based Trenchant BioSystems has partnered with engineering firm Invetech to develop a fully automated manufacturing platform it claims could cut production costs by up to 80%.

Lifecore and Indomo Sign New Deal to Develop Drug–Device Combination Acne Treatment
Lifecore and Indomo Sign New Deal to Develop Drug–Device Combination Acne Treatment

Under this new arrangement, the companies will work together to further develop Indomo’s DT-001 candidate, which will be combined with the ClearPen device to allow self-treatment of inflammatory acne lesions.

Charles River Laboratories Signs Deals to Sell CDMO and Discovery Assets
Charles River Laboratories Signs Deals to Sell CDMO and Discovery Assets

In efforts to streamline its portfolio and prioritize core capabilities, the company has agreed two separate transactions to divest its CDMO and Cell Solutions as well as select European Discovery Services sites.

Strategy

Featured
INTERPHEX 2026: The Multimodal Future of Sterile Manufacturing
INTERPHEX 2026: The Multimodal Future of Sterile Manufacturing

Automation and living contamination control strategies are helping to answer some of industry’s most pressing sterile manufacturing challenges, explains Dr. Laura Moody from Syntegon.

INTERPHEX 2026: Embedding Intelligence into Bioprocessing
INTERPHEX 2026: Embedding Intelligence into Bioprocessing

Customized engineering and embedded sensors are helping to turn passive single-use assemblies into intelligent, data-rich assets, reveals Rich Jones from Phillips Medisize.

INTERPHEX 2026: Managing Data Integrity in a Multimodal Pipeline
INTERPHEX 2026: Managing Data Integrity in a Multimodal Pipeline

Automated and single-use technologies are offering companies the transparency and agility needed for the newer, more complex drugs in the pipeline, explains Mike D’Avanzo from Alcami.

INTERPHEX 2026: The Continuous Conundrum
INTERPHEX 2026: The Continuous Conundrum

While the benefits of continuous manufacturing have been well-documented, regulatory alignment and complex control systems remain barriers to universal adoption, notes Mike Fazio from L.B. Bohle.

Future Biopharma

Featured
Tipping the Scales: The Benefits of Continuous Bioprocessing
Tipping the Scales: The Benefits of Continuous Bioprocessing

As cost pressures for drug developers persist, there is an inevitability that the industry will transition to continuous processes to overcome the limitations of traditional batch fed manufacturing.

A New Era for Excipients: Key Takeaways from the IPEC Europe Excipients Forum 2026
A New Era for Excipients: Key Takeaways from the IPEC Europe Excipients Forum 2026

Driven by regulatory evolution and a commitment to sustainability, the excipients’ sector is reinforcing its position as a sophisticated and credible stakeholder in the modern pharmaceutical supply chain.

Opening the Door: The Technology Scaling the Next Era of Emerging Therapies
Opening the Door: The Technology Scaling the Next Era of Emerging Therapies

As emerging therapies target increasingly niche genetic pathways, the adoption of AI modeling, organoids, and advanced AAV delivery is becoming essential to ensure successful clinical progression and patient access.

Transforming the Treatment Landscape with Tailored Therapies
Transforming the Treatment Landscape with Tailored Therapies

Patient outcomes are transforming, thanks to innovative, curative, tailored therapies; however, industry needs to address a few pressing issues to ensure the huge promise of these drugs can be achieved.

Regulatory

Featured
Roche's pMN Therapy Meets Primary Endpoint in Phase III Trial
Roche's pMN Therapy Meets Primary Endpoint in Phase III Trial

The company has revealed that its humanized, glycoengineered Type II anti-CD20 mAb has achieved superior complete remission rates versus tacrolimus in the MAJESTY study.

Rilzabrutinib Gains Regulatory Nods in the U.S. and Japan
Rilzabrutinib Gains Regulatory Nods in the U.S. and Japan

The U.S. FDA has granted breakthrough therapy designation and Japan’s MHLW has designated orphan drug status to Sanofi’s BTK inhibitor, rilzabrutinib (Wayrilz), as a treatment for wAIHA.

CBER Issues RTF for Moderna’s Investigational Flu Shot
CBER Issues RTF for Moderna’s Investigational Flu Shot

According to Moderna, the reasoning for the refusal to review the BLA by the regulatory authority is inconsistent with previous feedback, leading the company to request a Type A meeting.

FDA Grants Priority Review of sBLA for Datopotamab Deruxtecan
FDA Grants Priority Review of sBLA for Datopotamab Deruxtecan

If the application is successful, the therapy will become the first-line treatment for patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.

Upcoming Events

Featured
Drug Discovery Chemistry 2026

Drug Discovery Chemistry is a dynamic conference for medicinal, biophysical, and computational chemists working across pharma, biotech, and academia.

GLP-1-Based Therapeutics Summit 2026

The 3rd GLP-1 Based Therapeutics Summit comes at a defining moment as the industry transitions from the first wave of clinical success to a "billion-dollar pivot" toward multi-organ protection and specialized care.

Global Supply Chain and Logistics Summit 2026

The Supply Chain & Logistics Conference 2026 in Amsterdam brings industry leaders together to share practical insights and strategies for building resilient, future-ready supply chains.